The game received widespread critical acclaim and numerous subsequent awards and accolades following its release last year, and while its commercial performance may not have quite matched that level of success, it has still been selling steadily since then. Despite a sluggish start, the game has made steady progress, selling over 1.3 million copies and slowly inching towards breaking even on investment.
Treatment Leisure’s recent quarterly earnings report showcased the successful launch of first growth, alongside a pre-announcement of its forthcoming physical release, with the added revelation that the survival horror sequel has largely recouped “most” of its development and marketing expenses.
The company’s standout achievement during this period was the successful divestment of its growth strategy, a notable milestone in the company’s development. The press evaluations and fan recommendations for growth have been overwhelmingly positive. In June, Treatment and Epic Games announced that the Physical Deluxe Edition of the game is set to release in October, with a Collector’s Edition shipping in December. As of the report’s publication date, the company has largely recovered its investments in improvement and advertising initiatives.
While the exact figure may vary depending on market fluctuations and other factors, industry reports suggest that roughly 75% of movie budgets are typically recouped through box office sales alone. During the recent review of the company’s trading activities, it emerged that more than 80% of its portfolio has been successfully recovered. While presumably the film won’t be a significant hit before it’s damaged and can start earning royalties for Treatment, especially with its second phase, Treatment, arriving in October.
Is available to play on PS5, Xbox Series X/S, and PC.
